Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones
Turn Therapeutics Inc. (TTRX)
Company Research
Source: GlobeNewswire
WESTLAKE VILLAGE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, provides a shareholder update outlining continued progress in the advancement of its clinical programs while highlighting the flexibility of its financing strategy following its dilution-sparing direct listing. Capital Strategy and AlignmentTurn chose a direct listing structure to prioritize flexibility and long-term shareholder alignment. By bypassing traditional crossover rounds and IPO share issuance, early shareholders maintained their ownership positions. Through its $85 million GEM Global Yield agreement, the Company entered the market with a flexible, on-demand financing vehicle in place. This structure allows Turn to access capital opportunistically, at times and amounts determined by the Company, and eliminated the need for a traditional of
Show less
Read more
Impact Snapshot
Event Time:
TTRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TTRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TTRX alerts
High impacting Turn Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
TTRX
News
- Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Turn Therapeutics Appoints Martin Dewhurst to its Board of DirectorsGlobeNewswire
- Turn Therapeutics (NASDAQ:TTRX) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (e-)" rating on the stock.MarketBeat
- Turn Therapeutics (NASDAQ:TTRX) was upgraded by analysts at D Boral Capital to a "strong-buy" rating.MarketBeat
- Turn Therapeutics (NASDAQ:TTRX) was upgraded by analysts at D Boral Capital to a "strong-buy" rating.MarketBeat
TTRX
Sec Filings
- 1/12/26 - Form 8-K
- 1/7/26 - Form 8-K
- 12/12/25 - Form 4
- TTRX's page on the SEC website